
Evidence-Based Blood Therapeutics

At Dignity Health, patients—and their safety—are our priority. Evidence-based blood therapeutics is therefore crucial as overuse/inappropriate use of blood products poses a significant risk to patient safety.



PRBC Therapy Is An Organ Transplant—Patient Harm Due to Immunomodulation/Direct Toxicity



- Hospital Acquired Bacterial Infection Rates
- Incidence of Acute Myocardial Infarction
- Incidence of Re-bleeding - Cancer Recurrence Rates

OBJECTIVES

- Decrease the number of blood transfusions given to clinically stable patients with hemoglobin (Hgb) levels <a>7g/dL
- Where transfusion is clinically indicated, consider transfusing one unit of blood first instead of two



GOAL

7 is the

new

References: • Hébert PC et al. NEJM 1999;340:409-417 • Saltpeter, et al. Am J Med (2014) 127, 124-131

For additional research studies, supporting powerpoints, and videos, please visit: http://dignityhlth.org/CareManagementSharePoint